Research programme: vaginal infections therapeutics - Juniper Pharmaceuticals

Drug Profile

Research programme: vaginal infections therapeutics - Juniper Pharmaceuticals

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Columbia Laboratories
  • Developer Juniper Pharmaceuticals
  • Class Amides; Anti-infectives; Antiacnes; Oxidants; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Vaginitis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Vaginitis in USA (Vaginal)
  • 01 Apr 2015 Columbia Laboratories is now called Juniper Pharmaceuticals
  • 31 Dec 2008 Preclinical trials in Vaginitis in USA (Vaginal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top